Highest-materiality recent filing
Aytu BioPharma Q3 net loss $5.6M; EXXUA launch revenue $2.4M
Net revenue $12.4M, down 33% YoY from $18.5M; net loss $5.6M vs net income $4.0M.
Aytu BioPharma amends warrants to enable equity classification; expects liability reduction
Amended warrants from 2023 and 2025 offerings to clarify stockholder vote cannot change beneficial ownership blockers.
Aytu BioPharma Q2 fiscal 2026 net loss $10.6M; EXXUA launch generates $0.2M initial revenue
Net revenue $15.2M, down 6% YoY; net loss $10.6M vs net income $0.8M, includes $8.2M derivative warrant liability loss.
Aytu BioPharma launches EXXUA for MDD; reports $32.6M cash, reduced launch budget to $6-8M
EXXUA (gepirone) is first FDA-approved 5HT1a agonist for MDD; full commercial launch underway after Dec 15, 2025 initial availability.
Aytu BioPharma stockholders elect all director nominees, ratify auditor, approve say-on-pay
All five incumbent directors reelected: Disbrow, Donofrio, Dockery, Jain, Liu with majority votes.
Aytu BioPharma reports Q1 FY2026 revenue $13.9M, net income $2.0M; EXXUA launch on track
Net revenue $13.9M vs $16.6M year ago; ex-one-time rebate of $3.3M, revenue up 5% YoY.
Aytu BioPharma reports FY2025 net revenue $66.4M, net loss $13.6M; plans EXXUA launch in Q4 2025
Full year net revenue $66.4M (+2% YoY); net loss $13.6M vs $15.8M prior year; adjusted EBITDA $9.2M.
Aytu BioPharma terminates AR101 asset purchase agreement; rights transferred to EnzCo
Company transferred all rights, title and interest in AR101 to EnzCo on August 5, 2025.
Term loan principal increased to $13.0M from $11.1M; maturity extended to June 12, 2029.
Aytu BioPharma posts updated investor presentation highlighting EXXUA opportunity
Presentation posted on June 17, 2025 for use in upcoming investor meetings.
Aytu BioPharma closes $16.6M upsized public offering; EXXUA launch planned Q4 2025
Gross proceeds $16.6M from 1.37M shares at $1.50 and pre-funded warrants; overallotment fully exercised for 1.44M additional shares.
Aytu BioPharma secures exclusive U.S. commercialization rights to EXXUA (gepirone) for MDD
Upfront cash payment of $3M; second payment of $3M due 1-year post-launch, increasing to $5M if first-year net sales exceed $35M.
Aytu BioPharma prices $14.4M upsized public offering of common stock and prefunded warrants
Priced upsized public offering of 9,600,000 shares of common stock (or prefunded warrants) at $1.50 per share.
Aytu BioPharma shareholders approve 300,000-share increase to equity plan; all directors reelected
Shareholders approved Plan Amendment raising shares reserved under 2023 Equity Plan from 200,000 to 500,000 (increase of 300,000).
Aytu BioPharma Q3 FY2025 net income $4M, revenue up 32% YoY to $18.5M
Net income of $4.0M ($0.65 basic / $0.21 diluted EPS) vs net loss of $2.9M a year ago.
Aytu BioPharma reports Q2 net income $0.8M; Pediatric revenue up 86% sequentially
Net revenue $16.2M, down 13% YoY; ADHD revenue fell 17% to $13.8M, Pediatric rose 12% to $2.4M.
Aytu settles derivative shareholder suit; court hearing Jan 13, 2025
Settlement approval hearing scheduled for January 13, 2025 in Delaware Chancery Court.
Aytu BioPharma Q1 net income $1.5M; promotes Ryan Selhorn as CFO
Net income of $1.5M vs net loss of $8.1M YoY; diluted EPS $0.15 loss vs $1.48 loss.
Exclusive collaboration, distribution and supply agreement with Lupin Pharma Canada for Aytu's ADHD products.
Aytu BioPharma FY2024 revenue $81M, adjusted EBITDA $9.2M; ADHD net revenue +23%
FY2024 consolidated net revenue $81.0M (down 25% YoY); net loss $15.8M ($2.86/share)
Divested Consumer Health (Innovus Pharmaceuticals) to an undisclosed private e-commerce company after winding down operations.
Aytu BioPharma annual meeting elects all directors, ratifies auditor, approves say-on-pay
All five incumbent directors elected with majority votes; Joshua Disbrow received 2,111,846 for, 596,291 withheld.
Aytu refinances $15M term loan to $13M at ~12.4%, saving $1.3M interest
New $13M Eclipse term loan at SOFR+7% (~12.4%), replacing $15M Avenue loan at ~15.9%.
Aytu BioPharma Q3 fiscal 2024 positive adjusted EBITDA $0.4M; ADHD revenue up 49% YoY
Q3 net loss $2.9M ($0.52/sh) vs $7.2M loss prior year; positive adjusted EBITDA $0.4M.
On November 11, 2024, the board of directors of the Company (the " Board ") appointed Ryan Selhorn as Chief Financial Officer, Corporate Secretary and Treasurer of the Company.
On November 11, 2024, Mark K. Oki was terminated as Chief Financial Officer of the Company.
Max materiality 0.85 · Median 0.68 · Most common event earnings